At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Mar 11, 2026 at 13:01 ET
Solid Biosciences reported updated positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing robust microdystrophin expression, restoration of key muscle proteins, and improvements in biomarkers of muscle integrity and cardiac function. The therapy has been generally well tolerated in 40 participants, with plans for FDA discussions on a potential accelerated approval pathway in H1 2026 and a Phase 3 trial (IMPACT DUCHENNE) expected to begin dosing in Q1 2026.
- 40 participants dosed with SGT-003 in the INSPIRE DUCHENNE trial as of March 11, 2026
- Robust microdystrophin expression observed: 60% mean by western blot and 52% by mass spectrometry at Day 90
- Restoration of dystrophin-associated protein complex components: 60% beta-sarcoglycan-positive fibers and 35% nNOS activity-positive fibers at Day 90
- Mean reductions in muscle damage biomarkers: 38% in CK, 43% in ALT, 30% in AST, and 46% in LDH at Day 90
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access